Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Carcinoma, Hepatocellular 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Tumors 2Melanoma 2Carcinoma 2Breast Neoplasms 2Seminoma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Fibrosis 1Colorectal Neoplasms 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × ARQ 197 × Clear all
NCT01149720 2019-02-12

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Daiichi Sankyo

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumors

NCT01699061 2019-02-12

Effect of Tivantinib on the QTC Interval in Cancer Subjects

Daiichi Sankyo

Phase 1 Completed
38 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡